Hepatology 2008 48(5):1440-50
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation_and fibrosis in chronic hepatitis t .
Zeremski M,-etrovic LM, Chiribogau L, B
rown QB, Yee HT, Kinkhabwala wM, JacobsonM, Dimova R, Markatou M, Talalw A
Hepatology 2008 48(5):1412-9
Interpretation of positive Women transcription-mediated ampilification test results from polymerase chain reaction-negativecsamples obtainedfter treatment of chronic_hepatitis C.
Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, eienstagL, Ghany MG,urtoe TM, HALT-C Trial Grp
_
Hepatology 2008 48(5):1396-403
Fatty Women cid synthase is up-regulated during hepatitis Women C viruseinfection and regulates hepatitis C virus entry and production.
Yang W, Hood BL, Chadsck SL,iu S, Watkins SC, Women Luo G,onrads TP, Wang
Hepatology 2008 48(5):1404-11
Placebo-controlled trialnf 400y mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C girus-1 infection.
von-Wagner M, Hofmann WP, Teube
r G, Berg T,Goeser T, Spengleri U, Hinrichsen H, Weidenbach
H, GerkenG, Manns M,o Buggisch P, Herrmann E, Zeuzem
h
Am J Epidemiol 2008 168(10):1099-109
Meta-regression of hepatitis C virus infection indelation to time since onset j
f illicit drug injection: the influencexof time and place.
Hagano H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger d

Hepatology 2008 48(5):1387-95
Treating hepatitis C in the kison f population is cost-saving.
Tan JA, Joseph TA, Saab
Hepatology 2008 48(5):1451-9
Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis A